The Antitumor Effect of Hederagenin on Tumor's Growth of Hepatocarcinoma (H22) Tumor-Bearing Mice

Xue Bai,Baosheng Guan,Mingyuan Liu,Qiushuang Zhu,Yamei He,Peijun Wang,Yuan Wang,Qingwang Li
2017-01-01
Latin american journal of pharmacy
Abstract:Hederagenin (HI)), a derivative of oleanolic acid extracted from the leaves of ivy (Hedera helix L.), exhibited a variety of biological activities, including potent antitumor properties both in vitro and in vivo. In our study, effect of HD on the immunoregulation and anti-tumor were studied in H-22 tumor bearing miceImmunofluorescence by RT-PCR and Western blot. The results showed that tumor's weight was significantly decreased with HD treatment compared with that of the control group (P < 0.05). BD had no obvious toxicity and side effects on the liver and kidney. HD played a repair role in the injured thymus and spleen of H-22 tumor bearing mice and could increase the proliferation ability of lymphocytes in the spleen compared with that of the control group, and the difference was statistically significant (P < 0.01). The levels of IL-2 and TNF-alpha significantly increased in the HD 200 and 400 mg/kg group, respectively, compared with that of the control group, the difference was statistically significant (P < 0.05). The fluorescence intensity of the expression of the mutant P53 and Bcl-2 genes were significantly decreased in the HD groups compared with that of the control group (P < 0.01). The fluorescence intensity of P21 and Bax genes expression were significantly increased in the HD groups compared with that of control group (P < 0.01). The expression of Bcl-2 mRNA was decreased in HD groups compared with that of the control group, whereas the expression of Bax increased. The expression of Bcl-2 protein was decreased in HD groups compared with that of the control group, whereas the expression of Bax increased. All the results showed that BD would play an important role as anti-tumor drug.
What problem does this paper attempt to address?